Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.50 |
| ▸ | POLB | P06746 | 4/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.47 |
| ▸ | TYR | P14679 | 1/20 | 0.47 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.47 |
| ▸ | NQO2 | P16083 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1043638 | 0.84 | KDM4E (0.65) | KDM4EPOLBHSD17B10ALDH1A1HPGD | |
| SCHEMBL9849499 | 0.84 | POLB (0.62) | KDM4EPOLBHSD17B10ALDH1A1HPGD | |
| SCHEMBL11384616 | 0.83 | NCF1 (0.56) | KDM4EPOLBHSD17B10ALDH1A1HPGD | |
| SCHEMBL25912335 | 0.83 | DHODH (0.48) | KDM4EPOLBHSD17B10ALDH1A1HPGD | |
| SCHEMBL15798322 | 0.80 | KDM4E (0.73) | KDM4EPOLBHSD17B10ALDH1A1HPGD | |
| SCHEMBL4480591 | 0.80 | PLA2G2A (0.64) | KDM4EALDH1A1HPGDLMNAMEN1 | |
| SCHEMBL281969 | 0.80 | KDM4E (0.56) | KDM4EPOLBHSD17B10ALDH1A1HPGD | |
| SCHEMBL6652546 | 0.79 | ABCC8 (0.47) | KDM4EPOLBHSD17B10ALDH1A1HPGD | |
| SCHEMBL10610678 | 0.79 | KDM4E (0.71) | KDM4EALDH1A1HPGDLMNANQO2 | |
| SCHEMBL9359863 | 0.79 | ALDH1A1 (0.47) | KDM4EPOLBHSD17B10ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7060834-B2 | N-type calcium channel antagonists for the treatment of pain | ASTRAZENECA AB (SE) | 2006-06-13 | — | — | US | disclosed |
| US-20040266819-A1 | N-type calcium channel antagonists for the treatment of pain | ASTRAZENECA AB (SE) | 2004-12-30 | — | — | US | disclosed |
| EP-1430029-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2004-06-23 | — | — | EP | disclosed |
| WO-2003018560-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266819-A1 | N-type calcium channel antagonists for the treatment of pain | CACNA1E, CACNA1B, CACNA1G | KDM4E 4507/4885POLB 4496/4885HSD17B10 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.